Could a triple therapy beat back tough liver cancer?

NCT ID NCT06881433

Completed Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The goal was to see if the triple combination extends survival and shrinks tumors more than the standard two-drug approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hepatic arterial infusion chemotherapy (HAIC) added to immune checkpoint inhibitors and anti-VEGF drugs
What this could lead to: If successful, adding HAIC could improve survival and tumor shrinkage for people with advanced liver cancer that has spread into the portal vein.
What could go wrong: This is a completed study, but results are not yet published. Adding HAIC may increase side effects without clear benefit, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Zhongda Hospital

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.